CXADR

CXADR Molekülinformation

Englischer Name	Calcium sensing receptor	Anzahl der inverkehr gebrachten Arzneimittel	6
Anzahl der klinischen Arzneimittel	5	Target-Alias	Parathyroid cell calcium-sensing receptor 1，FHH，FIH，HHC，Receptors， Calcium-Sensing，Extracellular calcium-sensing receptor，hCasR，GPRC2A，Calcium Sensing Receptor，Parathyroid Ca(2+)-Sensing Receptor 1，Severe Neonatal Hyperparathyroidism，Calcium-Sensing Receptor，HYPOC1，NSHPT，PCaR1，EIG8，HHC1，CaSR，CAR，Hypocalciuric Hypercalcemia 1
Höchste Forschungs- und Entwicklungsphase	Approved

Englischer Name	Calcium sensing receptor
Target-Alias	Parathyroid cell calcium-sensing receptor 1，FHH，FIH，HHC，Receptors， Calcium-Sensing，Extracellular calcium-sensing receptor，hCasR，GPRC2A，Calcium Sensing Receptor，Parathyroid Ca(2+)-Sensing Receptor 1，Severe Neonatal Hyperparathyroidism，Calcium-Sensing Receptor，HYPOC1，NSHPT，PCaR1，EIG8，HHC1，CaSR，CAR，Hypocalciuric Hypercalcemia 1
Anzahl der inverkehr gebrachten Arzneimittel	6
Anzahl der klinischen Arzneimittel	5
Höchste Forschungs- und Entwicklungsphase	Approved

CXADR Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
His Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
CXR-H5222	Human	HEK293	Human CXADR / CAR Protein, His Tag				In den Warenkorb legen

Gesamtmenge1

CXADR Molekülhintergrund

Coxsackie virus and adenovirus receptor (CXADR) is also known as CAR, is a type I transmembrane glycoprotein for group B coxsackie viruses and subgroup C adenoviruses, and belongs to the CTX family of the Ig superfamily. CAR is strongly expressed in the developing central nervous system. It functions as a homophilic and also as a heterophilic cell adhesion molecule through its interactions with extracellular matrix glycoproteins such as: fibronectin, agrin, laminin-1 and tenascin-R. Human CXADR protein contains a signal sequence, a extracellular domain (ECD) with a V type (D1) and a C2 type (D2) Iglike domain, a transmembrane segment and a intracellular domain. D1 is thought to be responsible for homodimer formation in trans within tight junctions, and is necessary and sufficient for adenovirus binding. Variants of CXADR are attached to the cell membrane by a GPI- anchor.

CXADR Molekülalias

CXADR,CAR,CAR4,6,HCAR

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Encaleret sulfate	MK-5442; JTT-305; BBP-305; CLTX-305	Phase 3 Clinical	Japan Tobacco (Hong Kong) Ltd	Osteoporosis; Hypocalcemia; Osteoporosis, Postmenopausal; Hypoparathyroidism	Details
SHR-6508	SHR-6508	Phase 3 Clinical	Shanghai Hengrui Pharmaceutical Co Ltd	Hyperparathyroidism, Secondary; Kidney Diseases; Renal Insufficiency, Chronic; Hyperparathyroidism	Details
LNP-1892	LNP-1892	Phase 2 Clinical	Lupin Ltd	Hyperparathyroidism	Details
DS-9194b	DS-9194b	Phase 1 Clinical	Daiichi Sankyo Co Ltd	Osteoporosis	Details
RT-102(Rani)	RT-102	Phase 1 Clinical	Rani Therapeutics Holdings Inc	Osteoporosis	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Upacicalcet	SK-1403; AJT-240	Approved	Ajinomoto Co Inc	ウパシタ, Upasita	Japan	Hyperparathyroidism, Secondary	Sanwa Kagaku Kenkyusho Co Ltd	2021-06-23	Hyperparathyroidism, Secondary	Details
Parathyroid hormone (Shire)	SHP-634; ALX-111; 423562; NPSP-795; rhPTH (1-84); SHP-635; rhPTH-1-84; PTH (1-84); SB-423562; PTH 1-84; NPSP-558	Approved	Shire	Natpara, Preotact, Natpar	United States	Hypoparathyroidism	Nps Pharmaceuticals, Inc	2006-04-24	Osteoporosis; Bone Diseases, Endocrine; Osteoporosis, Postmenopausal; Hypocalcemia; Hypoparathyroidism; Hyperparathyroidism; Plaque psoriasis	Details
Cinacalcet Hydrochloride	AMG-073.HCl; NPS-1493; AMG-073; KRN-1493	Approved	Amgen Inc	Parareg, Sensipar, Mimpara, Regpara, 盖平, Sensipar/Mimpara	United States	Hypercalcemia; Hyperparathyroidism, Secondary	Amgen Inc	2004-03-08	Hyperparathyroidism, Secondary; Rejection of renal transplantation; Hypophosphatemia; Edema, Cardiac; Nephrosis; Renal Insufficiency; Parathyroid Neoplasms; Hypercalcemia; Kidney Diseases; Hyperparathyroidism, Primary; Prostatic Neoplasms; Osteomalacia; Renal Insufficiency, Chronic; Kidney Failure, Chronic; Hyperparathyroidism; Chronic Kidney Disease-Mineral and Bone Disorder	Details
Etelcalcetide Hydrochloride	ONO-5163; KAI-4169; AMG-416; KAI-4169-HCl	Approved	Amgen Inc	Parsabiv	EU	Hyperparathyroidism, Secondary	Amgen Europe Bv	2016-11-11	Hyperparathyroidism, Secondary; Edema, Cardiac; Renal Insufficiency, Chronic; Kidney Failure, Chronic	Details
Strontium Ranelate	S-12911; S-12911-2; FK-481	Approved	Laboratoires Servier	Osseor, Protos, Protelos, 欧思美	Mainland China	Osteoporosis, Postmenopausal	Les Laboratoires Servier	2004-09-20	Osteoporosis, Postmenopausal	Details
Evocalcet	KHK-7580; MT-4580	Approved	Mitsubishi Tanabe Pharma Corp	Orkedia	Japan	Hyperparathyroidism, Secondary	Kyowa Hakko Kirin Co Ltd	2018-03-23	Hyperparathyroidism, Secondary; Parathyroid Neoplasms; Hyperparathyroidism, Primary; Hyperparathyroidism	Details